Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Nurix Therapeutics, Inc. NRIX
$10.13
-$0.05 (-0.49%)
На 18:02, 12 мая 2023
+161.60%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
460694834.00000000
-
week52high
19.91
-
week52low
7.52
-
Revenue
38627000
-
P/E TTM
-3
-
Beta
1.68714800
-
EPS
-3.50000000
-
Last Dividend
0.00000000
-
Next Earnings Date
05 июл 2023 г. в 10:59
Описание компании
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | Buy | 12 июл 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 11 июл 2022 г. |
| JP Morgan | Overweight | Overweight | 08 июл 2022 г. |
| Baird | Outperform | Outperform | 08 июл 2022 г. |
| Wells Fargo | Overweight | Equal-Weight | 31 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 окт 2022 г. |
| Morgan Stanley | Equal-Weight | 11 окт 2022 г. | |
| SVB Leerink | Outperform | Outperform | 13 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hansen Gwenn | D | 38481 | 3207 | 30 янв 2023 г. |
| Hansen Gwenn | D | 23009 | 1412 | 30 янв 2023 г. |
| Hansen Gwenn | A | 24421 | 3207 | 30 янв 2023 г. |
| Ring Christine | D | 23089 | 1924 | 30 янв 2023 г. |
| Ring Christine | D | 7261 | 848 | 30 янв 2023 г. |
| Ring Christine | A | 8109 | 1924 | 30 янв 2023 г. |
| van Houte Hans | D | 34633 | 2886 | 30 янв 2023 г. |
| van Houte Hans | D | 76765 | 924 | 30 янв 2023 г. |
| van Houte Hans | A | 77689 | 2886 | 30 янв 2023 г. |
| Wolff Stefani | D | 11544 | 962 | 30 янв 2023 г. |
Новостная лента
Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
04 янв 2023 г. в 07:01
SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix's achievements in 2022 and major goals for 2023 at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:45 pm PT.
After Plunging -15.8% in 4 Weeks, Here's Why the Trend Might Reverse for Nurix Therapeutics, Inc. (NRIX)
Zacks Investment Research
28 дек 2022 г. в 10:51
Nurix Therapeutics, Inc. (NRIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting
GlobeNewsWire
07 дек 2022 г. в 16:01
Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET) Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET)
Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 187%: Read This Before Placing a Bet
Zacks Investment Research
04 ноя 2022 г. в 11:18
The consensus price target hints at an 187% upside potential for Nurix Therapeutics, Inc. (NRIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nurix Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire
02 ноя 2022 г. в 16:01
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer, will participate in the following conferences in November: